Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

CONTEXT Several lines of evidence have implied an association between Chlamydia pneumoniae infection and atherogenesis. OBJECTIVE To determine the effect of 12 weeks of antibiotic therapy on coronary heart disease events in patients with stable coronary artery disease and known C pneumoniae exposure. DESIGN, SETTING, AND PARTICIPANTS Randomized, placebo-controlled trial of 7747 adults with previous myocardial infarction that had occurred at least 6 weeks previously (median, 2.6 years) and a C pneumoniae IgG titer of 1:16 or more. Patients were recruited from 271 clinical practices in North America, Europe, Argentina, and India, from October 10, 1997, to July 22, 2001. INTERVENTION The patients received either azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2-12; n = 3879) or placebo (n = 3868). MAIN OUTCOME MEASURES The primary event was the first occurrence of death from any cause, nonfatal reinfarction, coronary revascularization, or hospitalization for angina. Patients were followed up until 1038 events accrued. RESULTS After a median of 14 months of follow-up, there was no significant risk reduction in the likelihood of a primary event with azithromycin vs placebo (7% [95% confidence interval, -5% to 17%], P =.23). Analysis of hazard ratios suggested early benefits of azithromycin on the primary event and on death or reinfarction, but these decreased over time. There were no significant risk reductions for any of the components of the primary end point including death (8%), recurrent myocardial infarction (7%), revascularization procedures (5%), or hospitalizations for angina (-1%). Adverse events related to study drug were reported by 13.2% of those randomized to receive azithromycin, predominantly a result of diarrhea, compared with 4.6% randomized to receive placebo, and resulted in discontinuation of drug in 1.6% of those taking azithromycin and 0.4% taking placebo. CONCLUSION Among stable patients with previous myocardial infarction and with evidence of C pneumoniae exposure, a 3-month course of azithromycin did not significantly reduce the clinical sequelae of coronary heart disease.

[1]  Grayston Jt.  Infections caused by Chlamydia pneumoniae strain TWAR. , 1992 .

[2]  D. Martin,et al.  In vitro infection of smooth muscle cells by Chlamydia pneumoniae , 1997, Infection and immunity.

[3]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[4]  A. Camm,et al.  Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction , 1997 .

[5]  G. Dahlén,et al.  Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. , 1995, Atherosclerosis.

[6]  M. Rosenfeld,et al.  Chlamydia pneumoniae Induces Inflammatory Changes in the Heart and Aorta of Normocholesterolemic C57BL/6J Mice , 2000, Infection and Immunity.

[7]  C. Bauters,et al.  Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. , 1994, Circulation.

[8]  S. Blankenberg,et al.  Impact of Infectious Burden on Extent and Long-Term Prognosis of Atherosclerosis , 2002, Circulation.

[9]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[10]  Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non–Q-Wave Coronary Syndrome , 2002, Circulation.

[11]  G. Zhong,et al.  Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR–/– mouse model within six months , 2000, Molecular and Cellular Biochemistry.

[12]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[13]  E J Topol,et al.  Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.

[14]  Y. Goo,et al.  Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Grayston Jt.  INFECTIONS CAUSED BY CHLAMYDIA PNEUMONIAE STRAIN TWAR , 1993 .

[16]  B. Horne,et al.  Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease: Primary Clinical Results of the ACADEMIC Study , 2000, Circulation.

[17]  J. Carlquist,et al.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. , 1998, Circulation.

[18]  E. Braunwald,et al.  Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction: A Thrombolysis In Myocardial Infarction 10 Substudy , 2000, Circulation.

[19]  E. Gurfinkel,et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.

[20]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[21]  L. Jackson.  Description and status of the azithromycin and coronary events study (ACES). , 2000, The Journal of infectious diseases.

[22]  M W Dunne,et al.  Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. , 2000, The Journal of infectious diseases.

[23]  I. Fong,et al.  Rabbit model for Chlamydia pneumoniae infection , 1997, Journal of clinical microbiology.

[24]  G. Zhong,et al.  The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. , 1999, The Journal of clinical investigation.

[25]  J. Kaski,et al.  Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection , 2002, Circulation.

[26]  M. Nieminen,et al.  SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.

[27]  M. Dunne.  The evolving relationship between Chlamydia pneumoniae and atherosclerosis , 2000, Current opinion in infectious diseases.

[28]  R. Kronmal,et al.  Chlamydia pneumoniae, Herpes Simplex Virus Type 1, and Cytomegalovirus and Incident Myocardial Infarction and Coronary Heart Disease Death in Older Adults: The Cardiovascular Health Study , 2000, Circulation.

[29]  J. Muhlestein,et al.  The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). , 2000, The Journal of infectious diseases.